Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Sustained Recovery of Uninvolved Heavy/Light Chain Pair Immunoparesis during Maintenance Discriminates Patients with Sustained Negative Minimal Residual Disease

Blood (2023) 142 (Supplement 1): 1958.

https://doi.org/10.1182/blood-2023-179452

Published: 2023

Journal Articles

Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma

Blood (2023) 142 (18): 1518–1528.

https://doi.org/10.1182/blood.2022019531

Published: 2023

Journal Articles

Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B-Cell Maturation Antigen (BCMA) × CD3 T-Cell Engager (TCE), Administered Subcutaneously (SC) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 First-in-Human Clinical Study

Blood (2023) 142 (Supplement 1): 2011.

https://doi.org/10.1182/blood-2023-180013

Published: 2023

Journal Articles

Belantamab Mafodotin in Combination with Vrd for the Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Results from the Phase II, Open Label, Multicenter, GEM-BELA-Vrd Trial

Blood (2022) 140 (Supplement 1): 7286–7288.

https://doi.org/10.1182/blood-2022-162584

Published: 2022

Journal Articles

Immune Biomarkers of Survival and Severe Infection in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with the Backbone Regimen Lenalidomide and Dexamethasone (Rd)

Catarina Maia, Noemi Puig, Cristina Pérez Ruiz, Maria Teresa Cedena Romero, Camila Guerrero, Marta Larrayoz, Cirino Botta, Norma C. Gutierrez, María José Calasanz, Maria Luisa Martin-Ramos, Miguel Hernández, Laura Rosinol Dachs, Esther González Garcia, Felipe De Arriba, Albert Oriol, Veronica Gonzalez-Calle, Fernando Escalante, Javier de la Rubia, Mercedes Gironella Mesa, Rafael Rios, Ricarda Belen Garcia Sanchez, Jose Maria Arguiñano PEREZ, Adrian Alegre, Jesus Martin, María del Carmen Couto Caro, Maria Casanova, Mario Arnao Herraiz, Ernesto Pérez, Sebastián Garzón López, Marta Sonia Gonzalez Perez, Guillermo Martín-Nuñez, Adriana Rossi, Morton Coleman, Cristina Encinas, Ana M. Vale, Ana Isabel Teruel, María Cortés Rodríguez, Jose A. Martinez-Climent, Juan-José Lahuerta, Joan Bladé Creixenti, Ruben Niesvizky, Jesús San-Miguel, Maria-Victoria Mateos, Bruno Paiva

Blood (2022) 140 (Supplement 1): 4200–4203.

https://doi.org/10.1182/blood-2022-163058

Published: 2022

Journal Articles

Immunoparesis Recovery in Transplant-Ineligible Newly Diagnosis Multiple Myeloma Patients: An Independent Prognosis Factor That Could Complement Prognostic Value of Minimal Residual Disease

Blood (2022) 140 (Supplement 1): 2344–2346.

https://doi.org/10.1182/blood-2022-166826

Published: 2022

Journal Articles

Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study

Blood (2022) 140 (Supplement 1): 400–402.

https://doi.org/10.1182/blood-2022-159009

Published: 2022

Journal Articles

Recovery of Uninvolved Heavy/Light Chain Pair Immunoparesis during Maintenance Is an Independent Prognostic Factor for Multiple Myeloma and Could Complement Prognosis Value of Minimal Residual Disease

Blood (2022) 140 (Supplement 1): 2101–2103.

https://doi.org/10.1182/blood-2022-167247

Published: 2022

Journal Articles

Ixazomib Plus Lenalidomide/Dexamethasone (IRd) Versus Lenalidomide /Dexamethasone (Rd) Maintenance after Autologous Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma: Results of the Spanish GEM2014MAIN Trial

Blood (2021) 138 (Supplement 1): 466.

https://doi.org/10.1182/blood-2021-146798

Published: 2021

Journal Articles

Severity of Covid-19 Clinical Outcomes and Mortality in Multiple Myeloma Patients over Year 1 of the Pandemic

Blood (2021) 138 (Supplement 1): 2719.

https://doi.org/10.1182/blood-2021-149192

Published: 2021

Journal Articles

Randomized Trial of Lenalidomide and Dexamethasone Versus Clarythromycin, Lenalidomide and Dexamethasone As First Line Treatment in Patients with Multiple Myeloma Not Candidates for Autologous Stem Cell Transplantation: Results of the GEM-Claridex Clinical Trial

Noemi Puig, MD PhD, Miguel T Hernández, Laura Rosinol Dachs, Esther González Garcia, MD, Felipe De Arriba, PhD, Albert Oriol, MD, Veronica Gonzalez-Calle, Fernando Escalante, MD, Javier De La Rubia, Mercedes Gironella Meda, Rafael Ríos Tamayo, Ricarda Belen Garcia Sanchez, José María Arguiñano Pérez, MD, Adrián Alegre Amor, MD, Jesús Martín, Norma C. Gutierrez, MD PhD, Maria Jose Calasanz, PhD BSc, Maria Luisa Martin-Ramos, María del Carmen Couto Caro, Maria Casanova, MD, Mario Arnao, MD, Ernesto Pérez Persona, Sebastián Garzón López, Marta Sonia Gonzalez, MD, Guillermo Martín Sánchez, MD, Adriana C. Rossi, MD MSc, Morton Coleman, MD, Cristina Encinas, Ana María Vale López, Ana Isabel Teruel, MDcal Doctor, Bruno Paiva, PhD, Maria Teresa Cedena Romero, MD PhD, Jesús San-Miguel, Juan Jose Lahuerta, MD PhD, Joan Bladé, MD, Ruben Niesvizky, MD, Maria-Victoria Mateos

Blood (2019) 134 (Supplement_1): 694.

https://doi.org/10.1182/blood-2019-123997

Published: 2019

Journal Articles

Biomarkers for Predicting Long-Term Disease Control in Transplant-Ineligible Multiple Myeloma Patients: The Presence of an MGUS- like Signature Is the Most Relevant Predictor

Blood (2018) 132 (Supplement 1): 4503.

https://doi.org/10.1182/blood-2018-99-117431

Published: 2018

Journal Articles

Activity and Safety of Daratumumab Monotheray in Patients with Relapsed and Refractory Multiple Myeloma Requiring Dialysis: Preliminary Results of Spanish, Retrospective, Multicenter Trial

Maria José Cejalvo, Mario Legarda, Eugenia Abella, Elena Cabezudo, Cristina Encinas, Ana García-Feria, Belén Iñigo, Jesús Marín, Paz Ribas, M. Ángeles Ruíz, Javier de la Rubia

Blood (2017) 130 (Supplement 1): 1866.

https://doi.org/10.1182/blood.V130.Suppl_1.1866.1866

Published: 2017

Journal Articles

The Poor Prognosis of High Cytogenetics Abnormalities in Elderly Patients Might be Overcome with an Optimized Total Therapy Approach Including Proteasome Inhibitors, Imid's Compounds and Alkylators

Blood (2016) 128 (22): 5688.

https://doi.org/10.1182/blood.V128.22.5688.5688

Published: 2016

Journal Articles

Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients

Blood (2016) 127 (25): 3165–3174.

https://doi.org/10.1182/blood-2016-03-705319

Published: 2016

Includes: Supplemental data

Journal Articles

Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM

Blood (2016) 127 (4): 420–425.

https://doi.org/10.1182/blood-2015-08-666537

Published: 2016

Journal Articles

Bortezomib Plus Melphalan and Prednisone (VMP) Followed By Lenalidomide and Dexamethasone (Rd) in Newly Diagnosed Elderly Myeloma Patients Overcome the Poor Prognosis of High-Risk Cytogenetic Abnormalities (CA) Detected By Fluorescence in Situ Hibridization (FISH)

Blood (2015) 126 (23): 4243.

https://doi.org/10.1182/blood.V126.23.4243.4243

Published: 2015

Journal Articles

Bortezomib, Melphalan, Prednisone (VMP) and Lenalidomide Plus Dexamethasone (Rd) Is the Optimal Combination for Patients with Newly Diagnosed Multiple Myeloma (MM) Patients Between 65 and 80 Years

Blood (2015) 126 (23): 1848.

https://doi.org/10.1182/blood.V126.23.1848.1848

Published: 2015

Journal Articles

Clinical Significance of Sensitive Flow-MRD Monitoring in Elderly Multiple Myeloma Patients on the Pethema/GEM2010MAS65 Trial

Blood (2014) 124 (21): 3390.

https://doi.org/10.1182/blood.V124.21.3390.3390

Published: 2014

Journal Articles

Novel Ex Vivo Assay Measures Drug-Induced Depletion of Hematopoietic Progenitors As an Estimate of Hematotoxicity

Blood (2014) 124 (21): 5785.

https://doi.org/10.1182/blood.V124.21.5785.5785

Published: 2014

NARROW

Sustained Recovery of Uninvolved Heavy/Light Chain Pair Immunoparesis during Maintenance Discriminates Patients with Sustained Negative Minimal Residual Disease

Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma

Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B-Cell Maturation Antigen (BCMA) × CD3 T-Cell Engager (TCE), Administered Subcutaneously (SC) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 First-in-Human Clinical Study

Belantamab Mafodotin in Combination with Vrd for the Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Results from the Phase II, Open Label, Multicenter, GEM-BELA-Vrd Trial

Immune Biomarkers of Survival and Severe Infection in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with the Backbone Regimen Lenalidomide and Dexamethasone (Rd)

Immunoparesis Recovery in Transplant-Ineligible Newly Diagnosis Multiple Myeloma Patients: An Independent Prognosis Factor That Could Complement Prognostic Value of Minimal Residual Disease

Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study

Recovery of Uninvolved Heavy/Light Chain Pair Immunoparesis during Maintenance Is an Independent Prognostic Factor for Multiple Myeloma and Could Complement Prognosis Value of Minimal Residual Disease

Ixazomib Plus Lenalidomide/Dexamethasone (IRd) Versus Lenalidomide /Dexamethasone (Rd) Maintenance after Autologous Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma: Results of the Spanish GEM2014MAIN Trial

Severity of Covid-19 Clinical Outcomes and Mortality in Multiple Myeloma Patients over Year 1 of the Pandemic

Randomized Trial of Lenalidomide and Dexamethasone Versus Clarythromycin, Lenalidomide and Dexamethasone As First Line Treatment in Patients with Multiple Myeloma Not Candidates for Autologous Stem Cell Transplantation: Results of the GEM-Claridex Clinical Trial

Biomarkers for Predicting Long-Term Disease Control in Transplant-Ineligible Multiple Myeloma Patients: The Presence of an MGUS- like Signature Is the Most Relevant Predictor

Activity and Safety of Daratumumab Monotheray in Patients with Relapsed and Refractory Multiple Myeloma Requiring Dialysis: Preliminary Results of Spanish, Retrospective, Multicenter Trial

The Poor Prognosis of High Cytogenetics Abnormalities in Elderly Patients Might be Overcome with an Optimized Total Therapy Approach Including Proteasome Inhibitors, Imid's Compounds and Alkylators

Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients

Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM

Bortezomib Plus Melphalan and Prednisone (VMP) Followed By Lenalidomide and Dexamethasone (Rd) in Newly Diagnosed Elderly Myeloma Patients Overcome the Poor Prognosis of High-Risk Cytogenetic Abnormalities (CA) Detected By Fluorescence in Situ Hibridization (FISH)

Bortezomib, Melphalan, Prednisone (VMP) and Lenalidomide Plus Dexamethasone (Rd) Is the Optimal Combination for Patients with Newly Diagnosed Multiple Myeloma (MM) Patients Between 65 and 80 Years

Clinical Significance of Sensitive Flow-MRD Monitoring in Elderly Multiple Myeloma Patients on the Pethema/GEM2010MAS65 Trial

Novel Ex Vivo Assay Measures Drug-Induced Depletion of Hematopoietic Progenitors As an Estimate of Hematotoxicity

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only